-
Jul 8, 2019-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial
-
May 29, 2019-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --
-
Apr 24, 2019Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019
-
Feb 20, 2019- STS101 for the acute treatment of migraine demonstrates highly differentiated pharmacokinetic (PK) profile in Phase 1 clinical trial